Should I buy or sell Voyager Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VYGR shares. View VYGR analyst ratings or view top-rated stocks .

What is Voyager Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 1-year price targets for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price. View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts .

How have VYGR shares performed in 2024?

Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR stock has decreased by 11.1% and is now trading at $7.50. View the best growth stocks for 2024 here .

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,330,000 shares, an increase of 44.2% from the March 15th total of 2,310,000 shares. Based on an average daily volume of 750,600 shares, the days-to-cover ratio is presently 4.4 days. View Voyager Therapeutics' Short Interest .

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our VYGR earnings forecast .

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%.

What ETFs hold Voyager Therapeutics' stock?

ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN) . Invesco Nasdaq Future Gen 200 ETF (QQQS) .

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU) , REGENXBIO (RGNX) , NVIDIA (NVDA) , Sorrento Therapeutics (SRNE) , TG Therapeutics (TGTX) , Amarin (AMRN) , CRISPR Therapeutics (CRSP) , Inovio Pharmaceuticals (INO) , Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT) .

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek , Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter. View institutional ownership trends .

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

→ Secret Bull Market Starts in This Unusual Sector (From Altimetry) (Ad)

Free VYGR Stock Alerts

$7.50

-0.05 (-0.66%)

(As of 04/19/2024 ET)

Compare

Today's Range: $7.28
▼
$7.66
50-Day Range: $7.15
▼
$10.54
52-Week Range: $6.06
▼
$14.34

Volume: 516,124 shs
Average Volume: 931,894 shs
Market Capitalization: $407.25 million

P/E Ratio: 2.43
Dividend Yield: N/A
Price Target: $19.33

Get Voyager Therapeutics alerts:

Voyager Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 157.8% Upside
$19.33 Price Target
Short Interest: Bearish
6.13% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.97
Upright™ Environmental Score
News Sentiment: 0.27
Based on 10 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.64) to ($1.49) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.00 out of 5 stars

Medical Sector

173rd out of 911 stocks

Biotechnology Industry

5th out of 33 stocks

3.4

Analyst's Opinion

Consensus Rating
Voyager Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Voyager Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.13% of the outstanding shares of Voyager Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Voyager Therapeutics has a short interest ratio ("days to cover") of 4.4.
Change versus previous month
Short interest in Voyager Therapeutics has recently increased by 44.16%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Voyager Therapeutics does not currently pay a dividend.
Dividend Growth
Voyager Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Voyager Therapeutics has received a 71.33% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Voyager Therapeutics is -0.97.

2.4

News and Social Media Coverage

News Sentiment
Voyager Therapeutics has a news sentiment score of 0.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 10 news articles for Voyager Therapeutics this week, compared to 6 articles on an average week.
Search Interest
Only 13 people have searched for VYGR on MarketBeat in the last 30 days. This is a decrease of -41% compared to the previous 30 days.
MarketBeat Follows
86 people have added Voyager Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 69% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Voyager Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Voyager Therapeutics is held by insiders.
Percentage Held by Institutions
48.03% of the stock of Voyager Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Voyager Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Voyager Therapeutics is 2.43, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.09.
Price to Earnings Ratio vs. Sector
The P/E ratio of Voyager Therapeutics is 2.43, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 227.14.
Price to Book Value per Share Ratio
Voyager Therapeutics has a P/B Ratio of 1.40. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

VYGR Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VYGR Stock News Headlines

April 18, 2024 | reuters.com

Louis Vuitton holds 'Voyager' fashion show in Shanghai

April 18, 2024 | yahoo.com

Nicolas Ghesquière’s First Voyager Show Was All About Chinese Youth

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 17, 2024 | msn.com

NASA tries to jog Voyager 1's memory from 15 billion miles away

April 17, 2024 | markets.businessinsider.com

Optimistic Buy Rating for Voyager Therapeutics Amid Strong Pipeline and Strategic Partnerships

April 16, 2024 | globenewswire.com

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

April 14, 2024 | americanbankingnews.com

Voyager Therapeutics (NASDAQ:VYGR) Shares Down 1.6%

April 12, 2024 | msn.com

DS9 Predicted Star Trek: Voyager’s Hologram Doctor Fighting For His Rights

April 19, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 12, 2024 | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Sees Significant Increase in Short Interest

April 11, 2024 | americanbankingnews.com

Voyager Therapeutics, Inc. (NASDAQ:VYGR) Given Average Rating of "Moderate Buy" by Brokerages

April 10, 2024 | msn.com

NASA Decodes the Reason Behind Voyager 1's Garbled Transmissions

April 9, 2024 | msn.com

Clarity Restored: NASA Pinpoints the Cause of Voyager 1’s Strange Data Signals

April 9, 2024 | finance.yahoo.com

Voyager Therapeutics, Inc.'s (NASDAQ:VYGR) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

April 9, 2024 | msn.com

NASA Has Finally Identified The Reason Behind Voyager 1's Gibberish

April 8, 2024 | msn.com

Recount Voyager 1's interstellar odyssey that outlived NASA expectations

April 8, 2024 | lse.co.uk

Voyager Life cancels merger with Northern Leaf as funding efforts fail

April 6, 2024 | forbes.com

NASA Discovers Source Of Voyager 1 Glitch In Interstellar Space

April 5, 2024 | msn.com

NASA engineers discover why Voyager 1 is sending a stream of gibberish from outside our solar system

April 5, 2024 | msn.com

NASA Figured Out Why Its Voyager 1 Probe Has Been Glitching for Months

April 5, 2024 | msn.com

Voyager’s Epochal Journey: A Billion-Year Odyssey Steered by Alan Cummings’ Dedication

April 5, 2024 | investing.com

Voyager Therapeutics COO sells shares worth over $13,000

April 3, 2024 | msn.com

NASA’s Ingenious Efforts to Restore Voyager 1’s Interstellar Communications on May，2022

March 31, 2024 | msn.com

Roddenberry’s Vision Reaffirmed Was Important To Star Trek: Voyager Showrunner

March 30, 2024 | msn.com

I’m Disappointed Star Trek: Voyager Couldn’t Save Season 2’s Most Interesting Character

March 27, 2024 | investorplace.com

The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio

March 26, 2024 | globenewswire.com

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

See More Headlines

Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/28/2024
Today: 4/19/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:VYGR
CUSIP: N/A
CIK: 1640266
Web: www.voyagertherapeutics.com
Phone: (857) 259-5340
Fax: N/A
Employees: 162
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $19.33
High Stock Price Target: $30.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +162.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): $3.09
Trailing P/E Ratio: 2.39
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $132.33 million
Net Margins: 52.93%
Pretax Margin: 53.49%
Return on Equity: 63.89%
Return on Assets: 40.79%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.96
Quick Ratio: 4.96

Sales & Book Value

Annual Sales: $250.01 million
Price / Sales: 1.60
Cash Flow: $2.88 per share
Price / Cash Flow: 2.56
Book Value: $5.37 per share
Price / Book: 1.37

Miscellaneous

Outstanding Shares: 54,300,000
Free Float: 51,749,000
Market Cap: $400.73 million
Optionable: Optionable
Beta: 0.96

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Alfred W. Sandrock Jr. (Age 66)
M.D., Ph.D., President, CEO & Director
Comp: $825.41k
Dr. Krystof Bankiewicz M.D.
Ph.D., Founder
Dr. Guangping Gao Ph.D.
Founder & Member of Scientific Advisory Board
Dr. Mark A. Kay M.D. (Age 65)
Ph.D., Founder
Dr. Phillip D. Zamore Ph.D.
Founder & Member of Scientific Advisory Board
Mr. Todd Carter Ph.D. (Age 54)
Chief Scientific Officer
Ms. Jacquelyn Fahey Sandell Esq.
J.D., Chief Legal Officer
Ms. Michelle Quinn Smith
Chief Human Resources Officer
Mr. G. Andre Turenne (Age 50)
Advisor
Comp: $600.3k
Dr. Maria Lopez-Bresnahan M.B.A.
M.D., Senior Vice President of Translational Medicine & Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VYGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings or view top-rated stocks.
What is Voyager Therapeutics' stock price target for 2024?: 7 Wall Street analysts have issued 1-year price targets for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's share price to reach $19.33 in the next twelve months. This suggests a possible upside of 157.8% from the stock's current price.
View analysts price targets for VYGR or view top-rated stocks among Wall Street analysts.
How have VYGR shares performed in 2024?: Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR stock has decreased by 11.1% and is now trading at $7.50.
View the best growth stocks for 2024 here.
Are investors shorting Voyager Therapeutics?: Voyager Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 3,330,000 shares, an increase of 44.2% from the March 15th total of 2,310,000 shares. Based on an average daily volume of 750,600 shares, the days-to-cover ratio is presently 4.4 days.
View Voyager Therapeutics' Short Interest.
When is Voyager Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VYGR earnings forecast.
How were Voyager Therapeutics' earnings last quarter?: Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Wednesday, February, 28th. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.59) by $1.84. The company had revenue of $90.06 million for the quarter, compared to analyst estimates of $4.95 million. Voyager Therapeutics had a net margin of 52.93% and a trailing twelve-month return on equity of 63.89%.

What ETFs hold Voyager Therapeutics' stock?: ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS).
What other stocks do shareholders of Voyager Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).
Who are Voyager Therapeutics' major shareholders?: Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends.
How do I buy shares of Voyager Therapeutics?: Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYGR) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

Voyager Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Voyager Therapeutics Stock (NASDAQ:VYGR)

VYGR Stock Price History

VYGR Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

VYGR Stock Analysis - Frequently Asked Questions

Overall MarketRank^™